Immuron Limited (ASX: IMC) announced that it has signed a strategic investment and option agreement with Ateria Health Limited. Ateria Health is a U.K. based biotech company that develops and distributes supplements for overall health. The Company has made strategic investment of ~AU$2.6 million (£1.5 million) to acquire initial 17.5% of Ateria Health. There is also an option for further investment of £1.47m, expiring on 31 July 2023.
This investment will allow the Company to further strengthen its position in the broader irritable bowel syndrome market and allows it to capitalise on opportunities working together with Arteria in the UK as well as Australia.
Further, Immuron intends to enter into reciprocal distribution contract for Travelan® in the U.K. market and JUVIATM in Australian & North American markets.
At AEDT 12:38 PM, IMU shares are trading at AU$0.080, down 1.234% from the previous close.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
